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 This study shows for the first time the effect that L-(+)-lactic acid has on mast cell 
activation. Lactic acid is a byproduct of anaerobic glycolysis and is associated with inflammatory 
environments such as wounds, tumors and, asthma. In this study, pre-treatment with lactic acid 
altered cytokine production by bone marrow-derived mast cells (BMMC). Specifically, lactic 
acid enhanced cytokine secretion following IgE cross-linking, but decreased IL-33 mediated 
cytokine production. These effects were altered by genetic background, since C57BL/6 mast 
cells demonstrated the aforementioned result, but lactic acid had no effect on IgE-mediated 
cytokine production in 129/SvJ mast cells. The affected cytokines included IL-6, TNF, MCP-1, 
MIP-1α, IL-13, and VEGF. Lactic acid pretreatment promoted a G0/G1 cell cycle arrest. 
Investigation into the IL-33 signaling pathway showed lactic acid decreased TAK1 and JNK 
phosphorylation, while increasing phosphorylated AKT levels. Blocking JNK and TAK1 with a 
small molecule inhibitor mimicked the effects of lactic acid. Interestingly, lactic acid 
significantly increased IL-33 mediated VEGF.  An in vitro angiogenesis assay confirmed that 
mast cells were pro-angiogenic in a lactic acid-rich environment. Taken together, these data 
show that lactic acid impacts mast cell function, possibly promoting a pro-angiogenic, anti-
inflammatory phenotype.
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Introduction 
 Mast cells are sentinels of the innate immune system, guarding the body against invading 
bacterial and parasitic infections. However, mast cells are best known for the major role they 
play in Type II hypersensitivities such as allergy and asthma. The binding of a harmless allergen 
to mast cell-bound IgE, and the subsequent signaling through the IgE receptor, FcεRI, result in a 
signaling cascade that forces the mast cell to release both early and late phase mediators (1-5). 
The early phase mediators, released within minutes of activation, include tryptases, chymases, 
histamine, prostaglandins, leukotrienes and Platelet Activating Factor (PAF), while the late phase 
mediators, released hours later, consist of IL-4, IL-5, IL-6, IL-10, IL-13, TNF, MIP-1α (1-5).  
 These factors produce the clinical symptoms of immediate hypersensitivity, including the 
skin wheal-and-flare response, itching, and vasodilation/edema. Mast cells can drive chronic 
disease such as asthma upon repeated exposure to the same allergens, which results in airway 
remodeling due to chronic inflammation mast cells cause (1-5).  
IgE crosslinking is not the only way mast cells are activated. IL-33 is a recently 
discovered alarmin in the IL-1 family produced by endothelial cells, epithelial cells, fibroblasts, 
and keratinocytes in response to damage or stress and promotes a TH2 response (6-10). Mast 
cells are one of the few cells in the body known to have the IL-33 receptor, ST2 (11). IL-33 
binding by mast cells results in the release of cytokines, chemokines and lipid mediators (6,7). 
IL-33 has also been shown to promote mast cell survival, maturation and adhesion (8,9,12). 
While IL-33 has been shown to be a poor inducer of degranulation, it augments degranulation 
triggered through the IgE receptor (6, 7). IL-33 has both protective and harmful effects. From a 
protective standpoint, IL-33 has beneficial effects in atherosclerosis, cardiac remodeling and 
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helminth infection (8). From an autoimmune standpoint, IL-33 has been linked to asthma, 
rheumatoid arthritis, multiple sclerosis, Type I diabetes, and skin inflammation (7, 13-23).  
 Inflammatory environments have specific changes in their microenvironments (9). A 
well-known example of this is the tumor microenvironment (TME). Tumors are known to 
preferentially undergo anaerobic glycolysis, even in the presence of sufficient oxygen, resulting 
in a hypoxic and lactic acid rich microenvironment with a low pH (10-16). These unique 
environmental factors can alter cellular responses, allowing tumors to escape immune 
surveillance (14, 17-19). There is sufficient evidence that the TME promotes tumor-associated 
macrophages (TAM) to take on an M2 phenotype, which is anti-inflammatory, and has reduced 
antigen presentation ability (11, 19). Tumor-derived lactic acid has also been shown to inhibit 
dendritic cell function, resulting in decreased proliferation and reduced antigen presentation (12). 
Among cytotoxic T cells, lactic acid decreases proliferation and inhibits their cytotoxic function 
(14).  Other examples of altered microenvironments that have increased lactate levels are 
obesity, hypertension and Type II diabetes, as well as tissues suffering injury, infection, 
inflammation or ischemia (17, 18, 20, 21).  
Mast cells are found in nearly all tissues except blood and can have phenotypic plasticity 
altered by microenvironmental factors, including SCF, IL-10, and TGFβ1 (22-25). Mast cells are 
also known to be one of the first cell types to invade into a developing tumor (26). The pro- or 
anti-tumorigenic role of mast cells has been argued either way (26, 27). The ability of mast cells 
to produce heparin, IL-8, VEGF, histamine, mitogenic factors, such as platelet-derived growth 
factor (PDGF), nerve GF (NGF), SCF, and proteases, collectively contribute to tumor survival, 
angiogenesis, metastasis, and escape form immune surveillance (27). However, mast cells can 
produce IL-1, IL-4, IL-6, and TNF that can induce tumor cell apoptosis, tryptase, which 
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stimulates protease-activated receptors and induces inflammation, and chondroitin sulfate, which 
could act as a decoy and inhibit metastases (27). Considering that lactic acid is known to alter 
cellular responses in inflammatory environments, and that lactic acid and mast cells are coming 
into direct contact in the body, an investigation into lactic acid effects on mast cell function is 
warranted.   
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Materials and Methods 
Animals 
 C57BL/6 and 129/SvJ mice were purchased form The Jackson Laboratory (Bar Harbor, 
ME) and used at a minimum of 6 weeks old, with approval from the Virginia Commonwealth 
University institutional animal care and use committee (IACUC).  
Mouse Mast Cell Cultures 
 Mouse bone marrow-derived mast cells (BMMCs) were derived by harvesting bone 
marrow aspirates from the femur of mice, followed by culture in complete RPMI (cRPMI) 1640 
medium (Invitrogen Life Technologies, Carlsbad, CA) containing 10% FBS, 2mM L-glutamine, 
100 U/ml penicillin, 100 µg/ml streptomycin, 1mM sodium pyruvate, and 1mM HEPES (all 
from Corning, Corning, NY), supplemented with IL-3-containing supernatant from WEHI-3B 
cells and SCF-containing supernatant from BHK-MKL cells. The final concentration of IL-3 and 
SCF were adjusted to 1ng/ml and 10ng/ml, respectively, as measured by ELISA. BMMC were 
used after 3 weeks of culture, at which point these primary populations are >90% mast cells, 
based on staining for c-Kit and FcεRI expression. 
Cytokines and Reagents 
 Recombinant mouse IL-3, SCF, and IL-33 cytokines as well as IL-6, TNF, and MCP-1 
ELISA kits were purchased from BioLegend (San Diego, CA). MIP-1α and VEGF ELISA kits 
were purchased form PeproTech (Rocky Hill, NJ). IL-13 ELISA kits were purchased from 
eBioscience (San Diego, CA). L-(+)-lactic acid and DNP-HSA were purchased from Sigma-
Aldrich (St. Louis, MO). 
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Cell Culture Conditions 
 For IgE-mediated activation, BMMC were first cultured overnight in cRPMI containing 
10ng/ml IL-3 and SCF, +/- IgE at a final concentration of 0.5 µg/ml. Cells were then washed and 
resuspended at 2x106 cells/ml in cRPMI with 20ng/ml IL-3 and SCF. An equal volume of 25mM 
lactic acid in cRPMI was added to the cell suspension, resulting in a final cell concentration of 
1x106cells/ml, 10ng/ml IL-3 and SCF, and 12.5mM lactic acid. Control conditions received 
cRPMI in place of lactic acid. After 6 hours of pretreatment in lactic acid media, cells then 
received 50ng/ml DNP-HSA for 16 hours, after which supernatant was collected. For IL-33 
activation, cells were cultured in lactic acid as described above for 24 hours, and then stimulated 
with 100ng/ml of IL-33 for 16 hours, after which supernatants were collected.  
Degranulation 
 BMMCs were cultured at 1x106 with IgE in either cRPMI or lactic acid media for 6 hours 
prior to IgE crosslinking with 50ng/mL of DNP-HSA, as described above. Cells were 
crosslinked for 45 minutes before being stained with CD63 and CD107a antibodies for X amount 
of time. Cells were then washed with PBS and resuspended in 200µl of FACS buffer. Samples 
were then run on a BD FACSCalibur (BD Biosciences). 
BMMC Receptor Flow Cytometry 
 Cells were cultured at 1x106/ml in either cRPMI or lactic acid media for 6 or 24 hours 
prior to staining. Afterwards, cells were washed in PBS twice, centrifuged and resuspended in 
FACS buffer (PBS/3% FBS/0.01% sodium azide) containing the indicated antibodies. Samples 
were incubated at 4oC for 30-45 minutes, washed twice with PBS, and resuspended in 200µl of 
FACS buffer. Samples were then analyzed using a on a BD FACSCalibur (BD Biosciences). 
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PI DNA Staining 
BMMCs were cultured at 50,000 cells/ml in variable amounts of IL-3/SCF (0/0, 1/10, 
1/25, 1/50 and 10/10 respectively) with or without 12.5.mM lactic acid for 36 hours. At the end 
of 36 hours, cells were washed in PBS and stored in Fixation Buffer (52.5% Ethanol, 35% PBS, 
12.5% FBS) for a minimum of 6 hours. Afterwards, cells were washed in PBS and stained 
incubated with PI Staining Buffer (PBS, RNase A, PI) for 2 hours in the dark at 4oC, followed by 
analysis with a BD FACSCalibur (BD Biosciences). 
Western Blotting 
Cells were cultured at 2x106/ml and lysed in Lysis Buffer (Cell Signaling Technology) 
supplemented with 1.5 ProteaseArrest (G-Biosciences, Maryland Heights, MO). Protein 
concentration was determined using the Pierce BCA protein assay kit (Thermo Scientific). 
Proteins were separated on 4-20% Mini-Protean TGX Gels (Bio-Rad, Hercules, CA) using 30µg 
of total protein per sample. Transfer was done onto nitrocellulose membranes, which were then 
blocked for 1 hour at room temperature with 2% BSA in PBS. Membranes were rinsed in PBS 
and then incubated overnight at 4oC in 0.1% TWEEN in PBS containing 2% BSA and primary 
antibody diluted 1:1000. Membranes were washed the next day with 0.1% TWEEN in PBS every 
5 minutes for a total of 30 minutes, then incubated with a 1:10,000 dilution of, either goat anti-
rabbit or mouse IgG (Jackson ImmunoResearch, West Grove, PA). Membranes were rinsed a 
final time before being read on an Odyssey CLx infrared scanner (Li-Cor, Lincoln, Nebraska). 
TAK1 and JNK Inhibitors 
A TAK1 inhibitor, (5Z)-7-Oxozeaenol, and JNK inhibitor, SP600125, were solubilized in 
dimethyl sulfoxide (DMSO), and used at working concentrations of 5uM and 10uM, 
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respectively. They were given added to cultures one hour prior to activation with 100ng/mL of 
IL-33. Supernatants were collected 16 hours later and ELISAs were run to determine cytokine 
production.  
miR-155 qPCR 
BMMCs were cultured in 12.5mM lactic acid for 6 hours. Then, cells were harvested and 
total RNA was extracted with TRIzol reagent (Life Technologies, Grand Island, NY). cDNA was 
synthesized using the qScript microRNA cDNA Syntheis Kit (Quantabio, Gaithersburg, MD) 
following the manufacturer’s protocol using oligo dT primers provided in the kit. cDNA was 
quantified using the Thermo Scientific NanoDrop™ 1000 UV–vis Spectrophotometer (Thermo 
Scientific, Waltham, MA) according to manufacturer’s recommended protocol. qPCR analysis 
was performed with Bio Rad CFX96 Touch™ Real-Time PCR Detection System (Hercules, CA) 
and SYBR® Green detection using a relative Livak Method. Each reaction was performed 
according to the manufacturer’s protocol using 8ng of sample cDNA, 12.5µl of PerfeCTa SYBR 
Green SuperMix (Quantabio, Gaithersburg, MD) and mmu-miR-155 or SNORD47 
(housekeeping gene) primers (Quantabio, Gaithersburg, MD) in a final reaction volume of 10 
µM. Amplification conditions for all reactions consisted of a heat-activation step at 95 °C for 
15 min followed by 40 cycles of 95 °C for 15s, 60 °C for 30s and 70 °C for 15s. Fluorescence 
data was collected during the extension step of the reaction.  
Statistical Analysis 
Data were analyzed using GraphPad Prism 6 software to determine p values by Student’s t test.  
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Results 
Lactic Acid Causes Differential Cytokine Production in C57BL/6 BMMCs Depending on 
Activation 
 Since mast cells in the body can reside in tissues that are rich in lactic acid, we cultured 
BMMCs in lactic acid rich media and measure the impact lactic acid has on cytokine secretion. 
Using ELISA, we measured IL-6, TNF, IL-13, MCP-1, and MIP-1α after IgE crosslinking or IL-
33 activation (Figure 1). We found that culturing C57BL/6 BMMCs in 12.5mM lactic acid media 
for 6 hours prior to IgE crosslinking led to a significant increase IL-6, TNF, MCP-1, and IL-13. 
By contrast, culturing BMMCs in 12.5mM lactic acid for 24 hours prior to IL-33 activation 
significantly decreased in production of these cytokines and chemokines.  
Lactic Acid Causes Differential Cytokine Production in 129/SvJ BMMCs Depending on 
Activation 
 Our lab has recently shown that mice from different backgrounds can have significantly 
different responses to identical treatments. For example, mast cells from 129/SvJ mice are 
resistant to the suppressive effects of TGFβ1 (25). Therefore, we expanded our investigation to 
include 129/SvJ BMMC. Using ELISA, we measured IL-6, TNF, MCP-1, IL-13 and MIP-1α 
after IgE crosslinking or IL-33 activation (Figure 2). We found that culturing 129/SvJ BMMCs 
in 12.5mM lactic acid media for 6 hours prior to IgE crosslinking did increases cytokine 
production as noted with C57BL/6 mice. However, culturing BMMCs in 12.5mM lactic acid for 
24 hours prior to IL-33 activation led to a significant decrease in IL-6, TNF, and IL-13. These 
data suggest that lactic acid effects can vary with both stimuli and genetic background.  
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Lactic Acid Increases VEGF Production and Angiogenesis 
 Because lactic acid is a byproduct of hypoxia, and hypoxia induces angiogenesis, 
investigated lactic acid effects on VEGF production. VEGF was measured by ELISA after 1 
hour of culture in 12.5mM lactic acid prior to activation by either IgE crosslinking or IL-33 
(Figure 3). We found that lactic acid did not change the amount of VEGF produced by IgE 
crosslinking on either C57BL/6 or 129/SvJ backgrounds. In contrast to its suppression of IL-33-
mediated cytokine and chemokine production, lactic acid significantly increased VEGF secretion 
from a C57BL/6 BMMC stimulated with IL-33, while having no effect on 129/SvJ BMMC. 
Lactic Acid Does Not Alter Degranulation 
 Since lactic acid significantly increases late phase cytokine secretion during IgE 
crosslinking, we wondered if lactic acid has the same effect on the early phase response, 
characterized by degranulation. Cells were cultured in 12.5mM lactic acid for 6 hours prior to 
IgE crosslinking with DNP-HSA. Measuring the granule markers CD63 and CD107a by cell 
surface staining, we demonstrate found lactic acid did not change BMMC degranulation (Figure 
4).  
Lactic Acid Arrests BMMCs in G0/G1 
 To determine whether lactic acid is toxic to BMMCs, we used PI DNA staining on 
fixed/permeabilized cells to assess cell cycle progression and the presence of fragmented DNA. 
Using variable amounts of IL-3 and SCF to induce cell cycle progression, cells were plated in 
either cRPMI or 12.5mM lactic acid for 36 hours. We discovered that lactic acid diminished the 
fraction of cells in the S and G2 phases, while increasing the G0/G1 phase. No increase in 
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apoptotic cells with sub-diploid DNA content was noted, suggesting that lactic acid is not toxic 
to BMMC under these culture conditions (Figure 5).  
Lactic Acid Does Not Change Receptor Expression 
 To determine a cause for the differential cytokine production caused by lactic acid, we 
assessed changes in surface receptor levels using flow cytometry. Cells were cultured in lactic 
acid for either 6 or 24 hours and then stained for receptors involved in IgE signaling (c-Kit and 
IgE) and IL-33 signaling (c-Kit and ST2) (Figure 6). The results showed a modest, 
approximately a 20% decrease, T/ST2 and c-Kit surface expression, and no change in FcεRI 
levels.  
Lactic Acid Effects on IL-33 Cytokine are pH-Dependent, while Effects on IgE are not 
 Previous papers demonstrated that pH plays a role in the ability of lactic acid to alter 
cellular function. To investigate this, we used sodium lactate, the salt of lactic acid does not alter 
pH when placed in cRPMI media. BMMCs were cultured in 12.5mM lactic acid media or 
12.5mM sodium lactate media for 24 hours prior to IL-33 activation. The results showed a clear 
difference. Lactic acid suppressed IL-33-mediated cytokine secretion as expected, while sodium 
lactate had no effect (Figure 7).  
BMMCs were also cultured in 12.5mM lactic acid media or 12.5mM sodium lactate 
media for 6 hours prior to IgE crosslinking. We found that sodium lactate was as effective as 
lactic acid at increasing IgE-mediated MIP-1α secretion (Figure 8). Hence the importance of 
lactic acid-induced pH change were divergent, depending on the stimulus.  
Lactic Acid Decreases Phosphorylation of TAK1 and JNK and Increases AKT Phosphorylation 
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 We chose to study the mechanism by which lactic acid alters IL-33 signaling, as these 
changes were greater in magnitude than the effect on IgE signaling. Western blots were 
performed on cells that were cultured in 12.5mM lactic acid prior to activation with IL-33. After 
normalization to GAPDH, results showed that phosphorylated JNK (pJNK) and phosphorylated 
TAK1 (pTAK1) are significantly reduced in lactic acid treated cells vs control BMMC. 
Phosphorylated AKT (pAkt) was significantly increased in lactic acid treated cells, while 
phosphorylated p38 (p-p38) and phosphorylated NFκB p65 (p-p65) were not significantly altered 
(Figure 9).  
TAK1 and JNK STIs Are Able to Mimic Lactic Acids Effect on IL-33 Signaling 
 The decrease in TAK1 and JNK activation correlated with the ability of lactic acid to 
reduce IL-33-mediated cytokine secretion. To determine if blocking these pathways alone was 
sufficient to mimic the effects of lactic acid, we treated BMMC with JNK and TAK1 chemical 
inhibitors. While the JNK inhibitor had no significant effect, TAK1 inhibition completely 
extinguished IL-33-mediated cytokine production (Figure 10). Thus, lactic acid effects on TAK1 
could be functionally important.  
Lactic Acid Decreases Expression of the Pro-Inflammatory Transcript, miR-155 
As part of our search for how lactic acid may be suppressing IL-33-mediated 
inflammatory signals, we measured expression of miR-155. This microRNA has been widely 
reported to promote inflammatory responses by controlling expression of many genes (28-31). 
As shown in Figure 11, we found that lactic acid treatment for 6 hours decreased miR-155 
expression by more than 50%, as measured by quantitative PCR. These data suggest lactic acid 
could have broad effects on mast cell function, by controlling this microRNA. 
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Discussion 
 Lactic acid is a byproduct of anaerobic glycolysis and is known to be increased in a 
variety of diseases such as cancer, obesity, Type II diabetes and wound healing (17, 21). While 
lactic acid has been shown to inhibit cytotoxic T cells ability to kill, promote M2 macrophage 
differentiation, and prevent dendritic cell antigen presentation, its effects on mast cell function 
have not yet been investigated (12, 14, 17). Mast cells are known to participate in allergic 
disease, parasitic infections, and resistance to bacteria. They have less defined roles in cancer 
and wound healing, but are known to participate in both (26, 32-35). Our data indicate that lactic 
acid alters inflammatory cytokine production in mast cells in a stimuli-dependent manner. In the 
context of cancer, this could lead to cancerous cells escaping immune surveillance. For wound 
healing, it could help strike the balance between a pro-resolving environment or allow for a 
chronic wound environment due to the inability to clear invading pathogens.  
 C57BL/6 mice exhibit increased cytokine production when exposed to lactic acid prior to 
IgE crosslinking, and exhibit decreased cytokine production when exposed to lactic acid prior to 
IL-33 activation. 129/SvJ mice exhibit the same inhibition of cytokine production when activated 
with IL-33. However, during IgE crosslinking with DNP-HSA, lactic acid does not increase 
cytokine production in129/SvJ mice as seen in the C57BL/6 BMMC. Differential responses 
between these two genetic backgrounds have been demonstrated before by our group and others 
(25, 36-38). These variations have potential clinical relevance, since human populations show 
varied tendencies to develop inflammatory diseases and varied therapeutic responses because of 
genetic variation.  C57BL/6 and 129/SvJ mice are known to differ in their default immune 
responses, with C57BL/6 mice mounting strong TH1 responses, and 129/Sv having strong TH2 
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responses. 129/SvJ mice are also more prone to autoimmunity (36). The reasons for their 
differential responses could be due to polymorphisms, such as those noted by Ford et al. in the 
CD23 sequence. Unraveling the mechanisms by which lactic acid alters mast cell function will 
provide targets for studying this difference. 
Based on previous work involving lactic acid, we also determined that the change in IL-
33 signaling is related with the change in pH (14). Sodium lactate is the salt of lactic acid, with 
the carboxyl group being replaced with an ionic bond to sodium. This results in sodium lactate 
not being able to donate a proton into solution and thus no pH change accompanies the addition 
of sodium lactate into media. Our results show that without the change in pH, cytokine and 
chemokine production induced by IL-33 were unaltered. Interestingly, the increase in cytokine 
and chemokine production that lactic acid causes during IgE crosslinking is not consistent when 
lactic acid or sodium lactate is added to BMMC cultures. This indicates that pH is not involved 
in the increase of IgE mediated cytokines and chemokines, and instead that the lactate structure 
itself is somehow driving the change. This warrants further investigation. Asthma leads to 
increased lactic acid and IL-33 production (39, 40). 
PI-DNA staining revealed that lactic acid did not elicit cell death in our culture 
conditions. However, lactic acid did appear to suppress proliferation, as shown by a slight but 
consistent increase in G0/G1 phase, matched by a 50% reduction in the S and G2 phases of the 
cell cycle. Lastly, we noted that in the absence of growth factors, BMMC cultured in lactic acid 
retained approximately 30% of the culture in the live, G0/G1 phase, compared to less than 10% 
of cells cultured without lactic acid. We hypothesize that this is related to the increase in Akt 
expression we noted in Western blots, as Akt promotes survival (41, 42). 
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Mast cells are known to secrete VEGF and participate in angiogenesis. Lactic acid has 
also been shown to induce VEGF production in macrophages (19). However, to our knowledge 
this has not been demonstrated in mast cells until now. Our data show that within an hour of 
lactic acid exposure, VEGF production significantly increased when following IL-33 stimulation. 
Combining this with the need for neovasculature needed for tumors to grow and wounds to heal, 
it appears as if the microenvironment is dictating the phenotype of the mast cell by using pH and 
hypoxia. Functional studies need to be carried out to test this hypothesis. 
Lactate has been shown to increase NFκB signaling in macrophages stimulated with LPS 
(17, 43). We investigated the mechanism by which lactic acid altered IL-33 signaling using 
western blots. IL-33 is known to activate the TAK1 MAP3K as an apical kinase, with resulting 
downstream activation of NFκB and JNK/p38 in mast cells (44). Our data show that while p38 
and NFκB p65 phosphorylation is not affected, TAK1 and JNK phosphorylation was 
significantly decreased and correlated with the decreased cytokine production seen in Figures 1 
and 2. The TAK1 inhibitor, (5Z)-7-Oxozeaenol completely ablated IL-6 and IL-13 production in 
response to IL-33, while chemical blockade of JNK had no effect. We therefore postulate that 
reduced TAK1 activation may be the critical mechanism by which lactic acid suppresses IL-33 
signaling. 
In conclusion, the lactic acid-rich environment associated with TME and wound healing 
affect mast cell-mediated inflammation in a stimulus and genetic background dependent manner.  
IL-33 activation in the presence of lactic acid gives an anti-inflammatory and pro-angiogenic 
response, while IgE crosslinking enhances cytokine and chemokine production. While further 
investigation is needed for more detailed mechanistic data as well as functional in vivo 
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experiments, this provides a potential starting point for developing therapies to mitigate 
inflammation in mast cell-dependent diseases.     
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 Figure 1: ELISAs were performed on 
activated by either IgE crosslinking or by IL
to 12.5mM lactic acid media for 6 hours prior to crosslinking. Cells that were activated with IL
33 were exposed to lactic acid for 24 hours prior to ac
C. MCP-1 ELISA. D. MIP-1α ELISA. E. IL
MIP-1α ELISA. Data shown are representative of at least 3 experiments with n=3 for each
experiment. * p<0.05, ** p<0.01, ***
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Figure 1A-H 
BMMC supernatants from C57BL/6 mice that were 
-33 stimulation. IgE crosslinked cells were exposed 
tivation. A. IL-6 ELISA. B. TNF
-6 ELISA. F. TNF ELISA. G. MCP-
 p<0.0005, ****p<0.000 
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 Figure 2: ELISAs were performed on 
activated by either IgE crosslinking or by IL
to 12.5mM lactic acid media for 6 hours prior to crosslinking. Cells that were activated with IL
33 were exposed to lactic acid for 24 hours prior to ac
C. MIP-1 α ELISA. D. MCP-1 ELISA. E. IL
shown are representative of at least 3 experiments with n=3 for each experiment.
p<0.01, *** p<0.0005, ****p<0.0001
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Figure 2A-G 
BMMC supernatants from 129/SvJ mice that were 
-33 stimulation. IgE crosslinked cells were exposed 
tivation. A. IL-6 ELISA. B. TNF
-6 ELISA. F. TNF ELISA G. MCP-
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 ELISA. 
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 * p<0.05, ** 
 
 Figure 3: VEGF ELISAs on BMMC supernatants 
activated by IL-33 stimulation. Data shown are representative of at least 3 experiments with n=3 
for each experiment. * p<0.05, ** 
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Figure 3A-B 
C57C57BL/6 and 129/SvJ mice that were 
p<0.01, *** p<0.0005, ****p<0.0001 
 
 
 
 
 
 Figure 4: C57BL/6 BMMCs were checked to see if lactic acid affected degranulation during IgE 
cross linking using two different surface markers, CD63 and CD107A. A) CD 63. B) CD107a.
Data shown are representative of at least 3 experiments with n=3 for each experimen
** p<0.01, *** p<0.0005, ****p
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Figure 4A-B 
<0.0001 
 
 
 
 
 
 
 
 
 
t. * p<0.05, 
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Figure 5A-D 
Figure 5: BMMC were cultured in variable amounts of IL-3 and SCF in the presence or absence 
of lactic acid for 36 hours, after which PI DNA staining was run on flow cytometry to determine 
cell phase progression. A. Cell death. B. G0/G1 phase. C. S phase. D. G2 phase. * p<0.05, ** 
p<0.01, *** p<0.0005, ****p<0.0001 
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Figure 6A-D 
Figure 6: BMMCs were checked by flow cytometry for changes in receptor expression in 
response to lactic acid pretreatment. Cells were pretreated in lactic acid for either 6 or 24 hours 
prior to receptor staining. A. MFI of T1/ST2 after 24 hours of lactic acid treatment. B. MFI of c-
kit after 24 hours of lactic acid treatment. C. MFI of anti-IgE after 24 hours lactic acid treatment. 
D. MFI of c-Kit after 6 hours lactic acid treatment. Data shown are representative of at least 3 
experiments with n=3 for each experiment. * p<0.05, ** p<0.01, *** p<0.0005, ****p<0.0001 
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Figure 7A-C 
Figure 7: BMMCs were given sodium lactate to determine if the decrease in cytokine production 
during IL-3 stimulation was related to pH. BMMCs were in lactic acid or sodium lactate media 
for 24 hours prior to IL-33 activation. A) IL-6 B) IL-13 C) MCP-1. Data shown are 
representative of at least 2 experiments with n=3 for each experiment. * p<0.05, ** p<0.01, *** 
p<0.0005, ****p<0.0001 
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Figure 8A-C 
Figure 8: BMMCs were given sodium lactate to determine if the increase in cytokine production 
during IgE crosslinking was due to pH. BMMCs were in lactic acid or sodium lactate media for 6 
hours prior to IgE crosslinking with DNP-HSA. A) MCP-1 B) TNF C) MIP-1α. Data shown are 
representative of at least 3 experiments with n=3 for each experiment. * p<0.05, ** p<0.01, *** 
p<0.0005, ****p<0.0001 
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Figure 9A-E 
C57BL/6 mice to determine the change lactic acid was 
. 15 minutes of IL-33 activation is shown as signal 
hospho-TAK1 B) Phospho-JNK C) Phospho
p<0.05, ** p<0.01, *** p<0.0005, ****p<0.0001
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Figure 10A-B 
Figure 10: TAK1 and JNK inhibitors were given to determine if they could mimic the effects of 
lactic acid on IL-33 signaling. A) IL-6 B) IL-13. * p<0.05, ** p<0.01, *** p<0.0005, 
****p<0.0001 
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 Figure 11: qPCR on mir155. Data shown are representative of at least 3 experiments with n=3 
for each experiment. * p<0.05, ** 
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Figure 11 
p<0.01, *** p<0.0005, ****p<0.0001 
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